Objective We examined whether plasma β-amyloid (Aβ) 42/Aβ40, as measured by a high-
precision assay, accurately diagnosed brain amyloidosis using amyloid PET or CSF p …

Background and Objectives To determine the diagnostic accuracy of a plasma Aβ42/Aβ40
assay in classifying amyloid PET status across global research studies using samples …

Currently, 3 amyloid PET tracers are approved and commercially available for clinical use.
They allow for the accurate in vivo detection of amyloid plaques, one hallmark of Alzheimer …

Importance Racial and ethnic groups with higher rates of clinical Alzheimer disease (AD) are
underrepresented in studies of AD biomarkers, including amyloid positron emission …

Introduction Levels of amyloid β peptide 42 (Aβ42), total tau, and phosphorylated tau-181
are well-established cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease, but …

Background Mild cognitive impairment (MCI) has an uncertain etiology and prognosis and
may be challenging for clinicians to discuss with patients and families. Amyloid imaging may …

Importance Previous studies have evaluated the diagnostic effect of amyloid positron
emission tomography (PET) in selected research cohorts. However, these research …

Background We evaluated Aβ misfolding in combination with Aβ 42/40 ratio as a prognostic
tool for future clinical progression to mild cognitive impairment (MCI) or dementia due to …

Importance The goal of Alzheimer disease (AD) prevention together with advances in
understanding the pathophysiology of AD have led to clinical trials testing drugs in …

Background Disclosure of amyloid positron emission tomography (PET) results to
individuals without dementia has become standard practice in secondary prevention trials …